• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Using preorchiectomy tumor marker serum concentrations for International Germ Cell Consensus Classification (IGCCCG) risk group assignment results in significant numbers of up- and downstaging].使用睾丸切除术前肿瘤标志物血清浓度进行国际生殖细胞共识分类(IGCCCG)风险组分配会导致大量分期上调和下调的情况。
Urologe A. 2021 Mar;60(3):337-343. doi: 10.1007/s00120-020-01432-1. Epub 2021 Jan 11.
2
Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.术前肿瘤标志物水平不应用于国际生殖细胞共识分类(IGCCCG)风险组分配。
J Cancer Res Clin Oncol. 2019 Mar;145(3):781-785. doi: 10.1007/s00432-019-02844-z. Epub 2019 Jan 14.
3
Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma.
Eur Urol Open Sci. 2023 Sep 9;56:25-28. doi: 10.1016/j.euros.2023.08.008. eCollection 2023 Oct.
4
Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment.肿瘤标志物水平的误用导致国际生殖细胞共识分类(IGCCCG)风险组分配不足和治疗效果受损。
Cancer Med. 2023 Aug;12(16):16829-16836. doi: 10.1002/cam4.6304. Epub 2023 Jul 1.
5
Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.临床A期非精原细胞性生殖细胞肿瘤中,原发肿瘤大小和睾丸切除术前血清肿瘤标志物水平对预测腹膜后淋巴结清扫病理分期的意义。
Urology. 2007 Mar;69(3):557-9. doi: 10.1016/j.urology.2006.12.011.
6
Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.IS 期睾丸生殖细胞癌患者的治疗和转归:来自西班牙生殖细胞癌协作组的回顾性研究。
J Urol. 2019 Oct;202(4):742-747. doi: 10.1097/JU.0000000000000366. Epub 2019 Sep 6.
7
The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).不同预后非精原细胞瘤生殖细胞肿瘤患者肿瘤标志物水平的预后影响:国际全球生殖细胞肿瘤协作组(G3)登记处。
Urol Oncol. 2019 Nov;37(11):809.e19-809.e25. doi: 10.1016/j.urolonc.2019.07.020. Epub 2019 Sep 5.
8
Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.残余肿瘤大小和 IGCCCG 风险分类预测生殖细胞肿瘤患者在残余肿瘤切除术后需要进一步血管介入治疗:德国睾丸癌研究组的一项多中心分析。
Eur Urol. 2012 Feb;61(2):403-9. doi: 10.1016/j.eururo.2011.10.045. Epub 2011 Nov 7.
9
[The role of tumour markers in diagnosis and management of testicular germ cell tumours].[肿瘤标志物在睾丸生殖细胞肿瘤诊断和管理中的作用]
Urologe A. 2011 Mar;50(3):313-21. doi: 10.1007/s00120-010-2414-5.
10
Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.白俄罗斯预后不良的转移性生殖细胞癌生存率低。
JCO Glob Oncol. 2021 Jan;7:63-71. doi: 10.1200/GO.20.00473.

引用本文的文献

1
Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment.肿瘤标志物水平的误用导致国际生殖细胞共识分类(IGCCCG)风险组分配不足和治疗效果受损。
Cancer Med. 2023 Aug;12(16):16829-16836. doi: 10.1002/cam4.6304. Epub 2023 Jul 1.

本文引用的文献

1
[Long-term effects of cisplatin-based chemotherapy in testicular cancer patients-what is important?].[顺铂化疗对睾丸癌患者的长期影响——要点何在?]
Urologe A. 2019 Oct;58(10):1212-1216. doi: 10.1007/s00120-019-1000-8.
2
Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.术前肿瘤标志物水平不应用于国际生殖细胞共识分类(IGCCCG)风险组分配。
J Cancer Res Clin Oncol. 2019 Mar;145(3):781-785. doi: 10.1007/s00432-019-02844-z. Epub 2019 Jan 14.
3
The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.生殖细胞肿瘤的新型生物标志物微小RNA - 371a - 3p在临床1期患者中衰减非常迅速。
Urol Int. 2018;100(4):470-475. doi: 10.1159/000488771. Epub 2018 Apr 26.
4
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.基于顺铂的标准化疗后睾丸癌幸存者的累积发病率负担:一项多机构研究。
J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4.
5
Long-term toxicity of cisplatin in germ-cell tumor survivors.顺铂对生殖细胞肿瘤幸存者的长期毒性
Ann Oncol. 2017 Nov 1;28(11):2670-2679. doi: 10.1093/annonc/mdx360.
6
Non-Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival.睾丸癌的非指南一致性治疗与无复发生存率降低相关。
Clin Genitourin Cancer. 2017 Sep 6. doi: 10.1016/j.clgc.2017.08.018.
7
Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer.遵循国家综合癌症网络®睾丸癌检测指南。
J Urol. 2017 Mar;197(3 Pt 1):684-689. doi: 10.1016/j.juro.2016.09.073. Epub 2016 Sep 20.
8
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.基于顺铂的化疗后成年期癌症幸存者听力障碍和耳鸣的综合听力测定分析
J Clin Oncol. 2016 Aug 10;34(23):2712-20. doi: 10.1200/JCO.2016.66.8822. Epub 2016 Jun 27.
9
Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer.睾丸癌患者化疗引起的急性心血管变化
J Clin Oncol. 2005 Dec 20;23(36):9130-7. doi: 10.1200/JCO.2005.01.4092. Epub 2005 Nov 21.
10
Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer.顺铂治疗睾丸癌10多年后循环血浆中的铂含量
Lancet. 2000 Mar 25;355(9209):1075-6. doi: 10.1016/s0140-6736(00)02044-4.

使用睾丸切除术前肿瘤标志物血清浓度进行国际生殖细胞共识分类(IGCCCG)风险组分配会导致大量分期上调和下调的情况。

[Using preorchiectomy tumor marker serum concentrations for International Germ Cell Consensus Classification (IGCCCG) risk group assignment results in significant numbers of up- and downstaging].

作者信息

Paffenholz Pia, Nestler Tim, Maatoug Yasmine, von Brandenstein Melanie, Köditz Barbara, Pfister David, Heidenreich Axel

机构信息

Klinik für Urologie, Uro-Onkologie, spezielle urologische und roboter-assistierte Chirurgie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland.

Department of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Deutschland.

出版信息

Urologe A. 2021 Mar;60(3):337-343. doi: 10.1007/s00120-020-01432-1. Epub 2021 Jan 11.

DOI:10.1007/s00120-020-01432-1
PMID:33427889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7979643/
Abstract

BACKGROUND

The prognostic classification system of the International Germ Cell Cancer Cooperative Group (IGCCCG) for testicular germ cell tumors is based on the histological subtype, location of the primary tumor, extent of metastatic spread and prechemotherapy tumor marker serum concentrations.

OBJECTIVES

In this study, we aim to identify whether the use of preorchiectomy instead of prechemotherapy tumor marker serum concentration has an impact on IGCCCG risk group assignment.

MATERIALS AND METHODS

We performed a retrospective analysis including 135 patients with metastasized testicular germ cell tumors. Analysis of the clinical information with a focus on the tumor marker serum concentration preorchiectomy and prechemotherapy was performed, thus leading to the grouping of patients according to IGCCCG risk group assignment.

RESULTS

Using preorchiectomy instead of prechemotherapy tumor markers led to an incorrect IGCCCG risk group classification in 8% (11/135) of all patients, and consequently to a non-guideline concordant treatment. Up-staging was observed in 8 of 11 patients, representing 6% (8/135) of the total patient cohort. Three of the 11 misclassified patients showed a down-staging and thus describe 2% (3/135) of the total patient cohort.

CONCLUSIONS

Using preorchiectomy tumor markers instead of prechemotherapy serum concentration might lead to an incorrect IGCCCG risk group assignment as well as non-guideline concordant treatment. Consequently, prechemotherapy tumor marker serum concentration should be applied for guideline concordant staging of patients.

摘要

背景

国际生殖细胞癌协作组(IGCCCG)的睾丸生殖细胞肿瘤预后分类系统是基于组织学亚型、原发肿瘤位置、转移扩散范围和化疗前肿瘤标志物血清浓度。

目的

在本研究中,我们旨在确定使用睾丸切除术前而非化疗前肿瘤标志物血清浓度是否会对IGCCCG风险组分配产生影响。

材料与方法

我们进行了一项回顾性分析,纳入了135例转移性睾丸生殖细胞肿瘤患者。重点分析了睾丸切除术前和化疗前的肿瘤标志物血清浓度临床信息,从而根据IGCCCG风险组分配对患者进行分组。

结果

使用睾丸切除术前肿瘤标志物而非化疗前肿瘤标志物导致8%(11/135)的患者IGCCCG风险组分类错误,进而导致不符合指南的治疗。11例患者中有8例出现分期上调,占总患者队列的6%(8/135)。11例分类错误的患者中有3例出现分期下调,占总患者队列的2%(3/135)。

结论

使用睾丸切除术前肿瘤标志物而非化疗前血清浓度可能导致IGCCCG风险组分配错误以及不符合指南的治疗。因此,化疗前肿瘤标志物血清浓度应用于患者的指南一致性分期。